Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > VH3 > RES-A059

resDetect™ VH3 ELISA Kit (Residue Testing)

For research use only.

Order Now

    Product Details
    Assay TypeSandwich-ELISA
    AnalyteVH3 binding Protein A
    Format96T
    Regulatory StatusRUO
    Sensitivity<50pg/mL
    Standard Curve Range50 pg/mL-8100 pg/mL
    Assay Time2 hr
    Suitable Sample TypeFor the quantitative determination of recombinant VH3 binding protein A
    Sample volume50ul
  • Background
    Traditional protein A have affinity for both the Fc region and the Fab VH3 region of human antibodies. But VH3 interacts only with the variable heavy chain of the VH3 sequence family of the human antibody,it can be widely used in the purification of related antibody drugs.. However, during the purification , VH3 may leach from the purification column and resulte in contamination of the antibody drugs prepared. Therefore, the detection of residual VH3 in antibody drugs purified from VH3 purification column is a key quality control step in the production process of antibody drug preparations.
  • Application

    The kit is developed for the detection of natural or structurally conserved recombinant forms of VH3 and a recombinant form of VH3 with very significant structural differences from natural VH3 such as MabSelect VH3 in Bioprocess manufacturing applications. It is used as a tool to aid in optimal purification process development and in routine quality control of in-process streams as well as final product .

    It is for research use only.

  • Storage
    1. Unopened kit should be stored at 2℃-8℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Materials Provided
    IDComponentsSize
    RES059-C01Pre-Coated Anti-VH3 Antibody Microplate1 plate
    RES059-C02Recombinant VH3 binding Protein A Standard (1μg/mL)100uL
    RES059-C03Biotin-Anti-VH3 Antibody1.5mL
    RES059-C04Streptavidin-HRP10ug
    RES059-C0510×Sample Dilution Buffer15mL
    RES059-C06Denaturation Buffer15mL
    RES059-C0720×Washing Buffer30mL
    RES059-C08Antibody Dilution Buffer15mL
    RES059-C09Streptavidin-HRP Dilution Buffer15mL
    RES059-C10Substrate Solution12mL
    RES059-C11Stop Solution8mL
Typical Data Please refer to DS document for the assay protocol.
 VH3 TYPICAL DATA

Detection of Recombinant VH3 binding Protein A by sandwich-ELISA Assay.
Immobilized Anti-VH3 binding Protein A Antibody can bind Recombinant VH3 binding Protein A. Detection was performed using Biotin-Anti-VH3 Antibody with sensitivity of 50 pg/mL (QC tested). For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The following example data is for reference only.

Validation
Intra-Assay Statistics

Three samples of known concentration were tested ten times on one plate to assess intra-assay precision.

 VH3 INTRA-ASSAY STATISTICS
Inter-Assay Statistics

Three samples of known concentration were tested in three separate assays to assess inter-assay precision.

 VH3 INTER-ASSAY STATISTICS
Recovery

Add different concentrations of VH3 binding Protein A (0.2ng/mL、1ng/mL、10ng/mL) to different concentrations of Human IgG4 (Toripalimab) (20mg/mL、10mg/mL、5mg/mL), then dilute the antibodies to a reasonable range, then test and calculated the concentration of VH3 binding protein A to give the recovery rate.

 VH3 RECOVERY
Interference effect

We have conducted interference effect test about frequently-used buffers, they have excellent buffer compatibility. For specific buffers, it is recommended that you verify recovery to determine the minimum dilution ratio.

 VH3 INTERFERENCE EFFECT
Specificity

Host cell protein (HCP 500 ng/mL) and host cell DNA (HCD 0.5 ng/mL) of HEK293, E.coli or CHO systems were added to human IgG1 (Bevacizumab, 1mg/mL) and human IgG4 (Toripalimab, 1mg/mL), respectively, which were higher than the usual quality standard limit. Then high, medium, and low concentrations of VH3 binding Protein A were added, respectively, and the ratio of VH3 binding Protein A recovery in the VH3 binding Protein A added samples without HCP and HCD was added as the specificity verification index. verification index.

 VH3 SPECIFICITY
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $550.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message